Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age.

Bone - 1 Mar 2016

Sinder Benjamin P, Lloyd William R, Salemi Joseph D, Marini Joan C, Caird Michelle S, Morris Michael D, Kozloff Kenneth M

Abstract excerpt

Bone composition and biomechanics at the tissue-level are important contributors to whole bone strength. Sclerostin antibody (Scl-Ab) is a candidate anabolic therapy for the treatment of osteoporosis that increases bone formation, bone mass, and bone strength in animal studies, but its effect on bone quality at the tissue-level has received little attention. Pre-clinical studies of Scl-Ab have recently expanded...

Topics

Join the communities discussing this publication.

Antibodies
Bone and Bones
Elastic Modulus
Femur
Glycoproteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Intercellular Signaling Peptides and Proteins

Osteogenesis Imperfecta

Source

Open in PubMed Open full text

Identifiers

PMID: 26769006
DOI: 10.1016/j.bone.2016.01.001
PMCID: PMC4757447

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age.PMID 26769006Read ↗

Sclerostin antibody enhances implant osseointegration in bone with Col1a1 mutation.Semantic proximity Read ↗

Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap–/– Mice, a Model of Recessive Osteogenesis ImperfectaSemantic proximity Read ↗

Bone mineral properties in growing Col1a2(+/G610C) mice, an animal model of osteogenesis imperfecta.Semantic proximity Read ↗

Bone Matrix Quality After Sclerostin Antibody TreatmentSemantic proximity Read ↗

Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice.Semantic proximity Read ↗

A proteomics approach to study mouse long bones: examining baseline differences and mechanical loading-induced bone formation in young-adult and old miceSemantic proximity Read ↗

Combination Treatment with Sclerostin and Dkk1 Antibodies Synergizes with Tibial Loading to Stimulate Bone Formation in Aged MiceSemantic proximity Read ↗

Sclerostin antibody treatment rescues the osteopenic bone phenotype of TGFβ inducible early gene-1 knockout female mice.Semantic proximity Read ↗

Makings of a brittle bone: Unexpected lessons from a low protein diet study of a mouse OI model.Semantic proximity Read ↗

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.Semantic proximity Read ↗

Morphological and mechanical characterization of bone phenotypes in the Amish G610C murine model of osteogenesis imperfecta.Semantic proximity Read ↗

An Additional Lrp4 High Bone Mass Mutation Mitigates the Sost-Knockout Phenotype in Mice by Increasing Bone Remodeling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.